Acacia Pharma
Harston Mill
Harston
Cambridge
CB22 7GG
United Kingdom
Tel: +44-(0)1223-875130
Fax: +44-(0)1223-875131
Website: http://www.acaciapharma.com/
41 articles about Acacia Pharma
-
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
6/9/2022
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year 1 addressable market and projected annual peak sales of $275 2 million in the U.S.
-
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
3/28/2022
Eagle Pharmaceuticals, Inc. announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc to Eagle by way of a scheme of arrangement under Part 26 of the United Kingdom’s Companies Act 2006.
-
New Jersey-based Eagle Pharmaceuticals, a company geared towards pharmaceutical hospital sales, has finalized terms to acquire Acacia Pharma Group, PLC.
-
Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™, an Ultra-short Acting and Reversible Anesthetic for Procedural Sedation
3/12/2020
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
-
Acacia Pharma Announces Changes to its Officers and Board of Directors
3/2/2020
Acacia Pharma Group plc, a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the following changes to its Officers and Board of Directors.
-
Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)
2/27/2020
Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients.
-
Acacia Pharma to Announce its Results for the Full Year 2019 on 2 March 2020 and Provides Notice of its Annual General Meeting
2/27/2020
Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), will announce its results for the full year ended 31 December 2019 on Monday 2 March 2020.
-
The green light from the U.S. Food and Drug Administration marks the first approval for U.K.-based Acacia.
-
Acacia Pharma Group plc announces planned CFO succession
1/13/2020
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/2014.
-
Acacia Pharma enters into strategic in-licensing, investment and loan transaction with Cosmo Pharmaceuticals N.V.
1/10/2020
• Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products • Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support commercial activities
-
Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
9/26/2019
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
-
Acacia Pharma Group plc - Interim Results for the Six Months ended 30 June 2019
9/5/2019
Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.
-
Acacia's founder will continue on in an advisory role while ViiV's departing CSO is eying multiple opportunities.
-
Acacia Pharma - Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
7/18/2019
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
-
Editorial on Positive Data for BARHEMSYS® Treatment of Post-Operative Nausea & Vomiting (PONV) Published in Anesthesia & Analgesia
7/12/2019
Acacia Pharma Group plc welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® as treatment of post-operative nausea & vomiting in patients who had not received prior prophylaxis*.
-
Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019
7/8/2019
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
-
ACACIA PHARMA’S BARHEMSYS® SIGNIFICANTLY IMPROVES POST-OPERATIVE NAUSEA & VOMITING (PONV) IN RESCUE TREATMENT OF AMBULATORY PATIENTS
5/10/2019
Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that an abstract reporting additional data and analyses from its positive Phase 3 clinical trial of BARHEMSYS®(intravenous amisulpride) as a rescue treatment for post-operative nausea & vomiting (PONV) has been selected for oral and posterpresentation at the 34th Annual Meeting of the Society for Ambulatory Anesthesia (SAMBA) in Austin, TX, USA (9-11 May).
-
ACACIA PHARMA: NOTICE OF ANNUAL GENERAL MEETING
5/7/2019
Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that its annual general meeting of shareholders (“AGM”) will be held at 11.00 am BST on Monday, 3 June 2019 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, UK.
-
ACACIA PHARMA ANNOUNCES POSITIVE PHASE 3 BARHEMSYS® RESCUE TREATMENT DATA TO BE PRESENTED AT THE ANNUAL CONGRESS OF ENHANCED RECOVERY AND PERIOPERATIVE MEDICINE
4/25/2019
Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as a rescue treatment of established post-operative nausea & vomiting (PONV) will be presented today in a poster at the 2019 Annual Congress of Enhanced Recovery and Perioperative Medicine in Washington, DC
-
ACACIA PHARMA TO ANNOUNCE ITS RESULTS FOR THE FULL YEAR 2018 ON WEDNESDAY 27 FEBRUARY
2/25/2019
Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, will announce its results for the full year ended 31 December 2018 on Wednesday 27 February.